Efficacy of topical risedronate and risedronate - eudragit complex in a model of cutaneous leishmaniasis induced by Leishmania (L.) amazonensis

PERALTA MF; GUZMAN ML; BRACAMONTE ME; MARCO JD; OLIVERA ME; CARRER DC; BARROSO PA

Buenos Aires

Encuentro; Reunión Anual de Sociedades de Biociencia 2020. SAIC.SAI.SAFIS 2020; 2020

Fundación Revista Medicina

EFFICACY OF TOPICAL RISEDRONATE AND RISEDRONATE - EUDRAGIT E COMPLEX IN A MODEL OF CUTANEOUS LEISHMANIASIS INDUCED BY LEISHMANIA (L.) AMAZONENSISAn efficacious topical treatment for cutaneous leishmaniasis (CL) is highly desirable but still an ongoing challenge. Systemic risedronate (Ris) has been reported to have anti-leishmania properties and Eudragit EPO (EuE) has shown in vitro activity against L. (L.) amazonensis. The aim of this work was to investigate the in vivo efficacy of topical Ris and EuE-Ris complexes on CL. Surface charge and Ris release kinetics from the different dispersions were analyzed. BALB/c mice were infected intradermally with promastigotes of L. (L.) amazonensis. Ulcers were treated with 100 µl of Ris or EuE-Ris hydrogels, both containing 2 mg of Ris, once a day from Monday to Friday during three weeks. All the lesions that received topical Ris or EuE-Ris showed an improvement with respect to control: reduction of ulcer average size, cicatrisation, flattened edges and no signs of necrosis. In addition, a marked parasitic inhibition of 69.5 and 73.7% was observed in the groups treated with Ris and EuE-Ris, respectively. The IgG2a/IgG1 ratio in mice treated with Ris (0.53) or EuE-Ris (0.4) showed higher levels than in the control group without treatment (0.29), indicating a tendency towards cure. The results are promising and the system should now be enhanced to achieve total parasite elimination.